| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Loss from continuing operations before income taxes | -32,900 | -18,282 | -26,184 | -26,820 |
| Income tax benefit (expense) | -1,216 | -609 | -151 | 118 |
| Net loss from continuing operations | -31,684 | -17,673 | - | - |
| Revenue | 26,693 | - | - | - |
| Cost of revenue | 14,352 | - | - | - |
| Gross profit | 12,341 | - | - | - |
| Selling, general and administrative expenses | 8,474 | - | - | - |
| Research and development | 4,849 | - | - | - |
| Transaction expenses | 2,203 | - | - | - |
| Other (income) expense, net | -181 | - | - | - |
| Total operating expenses | 15,345 | - | - | - |
| Loss from discontinued operations before income taxes | -3,004 | - | - | - |
| Income tax benefit (expense) | -1 | - | - | - |
| Loss from discontinued operations, net of tax | -3,003 | -15,786 | - | - |
| Net loss | -34,687 | -33,459 | -26,033 | -26,938 |
| Induced conversion of redeemable preferred stock | 0 | 0 | - | - |
| Net loss attributable to common stockholders | -34,687 | -33,459 | - | - |
| Earnings per share, basic | -0.09 | -0.09 | -0.07 | -0.07 |
| Earnings per share, diluted | -0.09 | -0.09 | -0.07 | -0.07 |
| Weighted average number of shares outstanding, basic, total | 382,630,000 | 380,498,000 | 378,228,000 | 371,538,000 |
| Weighted average number of shares outstanding, diluted, total | 382,630,000 | 380,498,000 | 378,228,000 | 371,538,000 |
STANDARD BIOTOOLS INC. (LAB)
STANDARD BIOTOOLS INC. (LAB)